ClinicalTrials.gg
TerminatedNCT01342016Updated Oct 17, 2014

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

A Phase 3 interventional study of tacrolimus capsule and tacrolimus placebo in Lupus Nephritis, sponsored by Astellas Pharma Inc. Terminated at 12 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-17.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to safety concern of active control drug

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing tacrolimus in Lupus Nephritis — 1 open to participants now, 1 under way, none of them phase 3. Tacrolimus · Lupus Nephritis.

Enrollment
7th of 16
84 · median 73
Started
2011
with 3 others
Phase 3
7 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
2 of 16
Astellas Pharma Inc

Among the 16 studies testing tacrolimus in Lupus Nephritis, this one is the 7th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 13th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

1 of the 16 studies testing tacrolimus in Lupus Nephritis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tacrolimus in Lupus Nephritis, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of tacrolimus capsules with leflunomide tablets in the treatment of lupus nephritis.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • prograf
  • nephritis
  • leflunomide
  • immunosuppressant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • body weight 40-100kg
  • diagnosed as systemic lupus erythematosus, (according to American College of Rheumatology Diagnostic Criteria,1997)
  • diagnosed as type III/ IV of lupus nephritis by renal within 6 months
  • 24hr proteinuria ≥2g and/or active urinary sediments

Exclusion criteria

Exclusion Criteria:

  • receiving
  • receiving routine treatment of tacrolimus and leflunomide within 1 month
  • receiving nonsteroidal anti-inflammatory drugs (NSAIDs) within 1 months before the study
  • history of allergy to tacrolimus and leflunomide
  • anticipated maintenance dialysis persisted over 8 weeks; or already being dialyzed over 2 weeks before recruitment
  • planning to receive kidney transplantation or in the near future or having a history of undergoing kidney transplantation
  • serum creatinine (Scr) ≥3mg/dl or estimated (eGFR) \< 30ml/min
  • diabetes mellitus patients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    tacrolimus group

    tacrolimus capsule + leflunomide placebo

    Drug: tacrolimus capsule · Drug: leflunomide placebo · Drug: prednisone

  • Active comparator
    leflunomide group

    tacrolimus placebo + leflunomide tablet

    Drug: tacrolimus placebo · Drug: leflunomide tablet · Drug: prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. remission rate (partial remission + complete remission)

    Time frame: at 6 months after treatment

Secondary outcomes

  1. urinary protein excretion for 24 hrs (24hr proteinuria)

    Time frame: at 12 weeks and 24 weeks

  2. serum albumin level

    Time frame: at 12 weeks and 24 weeks

  3. serum creatinine level

    Time frame: at 12 weeks and 24 weeks

  4. estimated glomerular filtration rate (eGFR)

    Time frame: at 12 weeks and 24 weeks

07

Study locations

12 sites
  • Beijing, China
  • Fujian, China
  • Hubei, China
  • Hunan, China
  • Jiangsu, China
  • Jilin, China
  • Liaoning, China
  • Shandong, China
  • Shanghai, China
  • Shanxi, China
  • Sichuan, China
  • Zhejiang, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2011
First posted
Apr 26, 2011
Start
Apr 2011
Primary completionActual
May 2013
CompletionActual
May 2013
Last update
Oct 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01342016
Responsible party
Sponsor
First posted
Apr 26, 2011
Start date
Apr 2011
Primary completion
May 2013
Completion
May 2013
Last update
Oct 17, 2014

Study contacts

Use Central Contact
study chair · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion